Nemus Biosciences develops cannabinoid-based therapeutics using proprietary technology licensed from the University of Mississippi and explores natural and synthetic compounds alone or in combination. The company is working on novel delivery approaches intended to optimize clinical effects while limiting adverse events. Management says the strategy includes advancing candidate molecules toward clinical-stage testing and pursuing strategic partnerships with larger pharmaceutical companies. Nemus is led by executives with experience in early-stage drug development. The company announced it will use proceeds from its recent financing to fund research and development activities and for general corporate and working capital purposes.

Total raised

$20M

Funding rounds

1

Latest round

Series E

Latest activity

May 2017